JBIO

SEC source: 0001415889-24-004903 · form4-02222024_060201.xml · nonDerivative · entry 1

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-24-002957 · form4-02072024_060201.xml · derivative · entry 8

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,732

Underlying: Common Stock · 1,500 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F7 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

SEC source: 0001415889-24-002957 · form4-02072024_060201.xml · derivative · entry 7

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,908

Underlying: Common Stock · 1,200 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F6 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

SEC source: 0001415889-24-002957 · form4-02072024_060201.xml · derivative · entry 6

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,894

Underlying: Common Stock · 500 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F5 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.

SEC source: 0001415889-24-002957 · form4-02072024_060201.xml · derivative · entry 5

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,088

Underlying: Common Stock · 500 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F4 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-24-002957 · form4-02072024_060201.xml · derivative · entry 4

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,308

Underlying: Common Stock · 900 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-24-002957 · form4-02072024_060201.xml · nonDerivative · entry 3

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,609

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.16 to $18.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001415889-24-002957 · form4-02072024_060201.xml · nonDerivative · entry 2

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,209

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

SEC source: 0001415889-24-002957 · form4-02072024_060201.xml · nonDerivative · entry 1

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

SEC source: 0001415889-24-002089 · form4-01312024_060101.xml · derivative · entry 1

NOYES TIMOTHY P · CIK 0001185035 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-01-28

F1 · derivative.exercise_date: The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 29, 2024.

SEC source: 0001415889-24-001775 · form4-01242024_060107.xml · derivative · entry 1

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,586

Underlying: Common Stock · 66,586 shares

Expires 2034-01-21

F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.

SEC source: 0001415889-24-001777 · form4-01242024_060110.xml · derivative · entry 2

Pigot Timothy · CIK 0001967140 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,586

Underlying: Common Stock · 66,586 shares

Expires 2034-01-21

F2 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.

SEC source: 0001415889-24-001773 · form4-01242024_060101.xml · derivative · entry 1

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,586

Underlying: Common Stock · 66,586 shares

Expires 2034-01-21

F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.

SEC source: 0001415889-24-001774 · form4-01242024_060106.xml · derivative · entry 1

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,586

Underlying: Common Stock · 66,586 shares

Expires 2034-01-21

F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.

SEC source: 0001415889-24-001776 · form4-01242024_060108.xml · derivative · entry 1

Verwijs Marinus · CIK 0001916553 · CHIEF TECHNOLOGY OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,586

Underlying: Common Stock · 66,586 shares

Expires 2034-01-21

F1 · derivative.exercise_date: The option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.

SEC source: 0001415889-24-001772 · form4-01242024_060102.xml · derivative · entry 1

Eldridge George A · CIK 0001413006 · SEE REMARKS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,586

Underlying: Common Stock · 66,586 shares

Expires 2034-01-21

F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024.

SEC source: 0001415889-24-001609 · form4-01192024_060101.xml · derivative · entry 3

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,027

Underlying: Common Stock · 4,000 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F2 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-24-001609 · form4-01192024_060101.xml · nonDerivative · entry 2

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,251

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-24-001609 · form4-01192024_060101.xml · nonDerivative · entry 1

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,251

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · derivative · entry 9

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,232

Underlying: Common Stock · 1,500 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F8 · derivative.exercise_date: A total of 59,732 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · derivative · entry 8

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,108

Underlying: Common Stock · 1,200 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F7 · derivative.exercise_date: A total of 49,908 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on July 4, 2021.

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · derivative · entry 7

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,394

Underlying: Common Stock · 500 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F6 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with options vesting in 48 equal monthly installments, with the first installment vested on May 2, 2021.

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · derivative · entry 6

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,588

Underlying: Common Stock · 500 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F5 · derivative.exercise_date: A total of 14,488 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on June 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · derivative · entry 5

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,208

Underlying: Common Stock · 900 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F4 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of this option vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · nonDerivative · entry 4

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,609

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.375 to $19.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · nonDerivative · entry 3

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,083

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.315 to $19.30, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · nonDerivative · entry 2

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,209

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

SEC source: 0001415889-24-000818 · form4-01082024_060101.xml · nonDerivative · entry 1

NIVEN RALPH · CIK 0001168060 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,009

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 25, 2023.

SEC source: 0001415889-24-000706 · form4-01042024_060111.xml · derivative · entry 1

Santel Donald J · CIK 0001293630 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,889

Underlying: Common Stock · 2,889 shares

Expires 2034-01-01

F1 · kind: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

F1 · derivative.exercise_date: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

SEC source: 0001415889-24-000705 · form4-01042024_060109.xml · derivative · entry 1

Dable Habib J · CIK 0001690773 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,964

Underlying: Common Stock · 2,964 shares

Expires 2034-01-01

F1 · kind: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

F1 · derivative.exercise_date: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

SEC source: 0001415889-24-000704 · form4-01042024_060107.xml · derivative · entry 1

Katabi Maha · CIK 0001720685 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,519

Underlying: Common Stock · 3,519 shares

Expires 2034-01-01

F1 · kind: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

F1 · derivative.exercise_date: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

SEC source: 0001415889-24-000703 · form4-01042024_060104.xml · derivative · entry 1

GRAYZEL DAVID S. · CIK 0001732786 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,186

Underlying: Common Stock · 3,186 shares

Expires 2034-01-01

F1 · kind: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four substantially equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

F1 · derivative.exercise_date: This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four substantially equal installments, with the first installment vesting on March 31, 2024, the second installment vesting on June 30, 2024, the third installment vesting on September 30, 2024, and the fourth installment vesting on December 31, 2024.

F2 · ownership.direct: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

SEC source: 0001415889-23-017025 · form4-12292023_061202.xml · derivative · entry 4

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,540

Underlying: Common Stock · 100 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F3 · derivative.exercise_date: A total of 109,640 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, with shares vesting in 48 substantially equal monthly installments.

SEC source: 0001415889-23-017025 · form4-12292023_061202.xml · derivative · entry 3

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,269

Underlying: Common Stock · 25 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F2 · derivative.exercise_date: A total of 16,294 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.

SEC source: 0001415889-23-017025 · form4-12292023_061202.xml · nonDerivative · entry 2

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,251

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-23-017025 · form4-12292023_061202.xml · nonDerivative · entry 1

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,376

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-23-016908 · form4-12222023_061202.xml · derivative · entry 4

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,027

Underlying: Common Stock · 1,076 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-23-016908 · form4-12222023_061202.xml · derivative · entry 3

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,023

Underlying: Common Stock · 2,924 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F2 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-23-016908 · form4-12222023_061202.xml · nonDerivative · entry 2

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,251

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-23-016539 · form4-12152023_061201.xml · derivative · entry 8

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,306

Underlying: Common Stock · 7,197 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-23-016539 · form4-12152023_061201.xml · derivative · entry 7

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,744

Underlying: Common Stock · 2,700 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F2 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-23-016539 · form4-12152023_061201.xml · nonDerivative · entry 4

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,251

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-23-016539 · form4-12152023_061201.xml · nonDerivative · entry 3

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,148

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-23-016539 · form4-12152023_061201.xml · derivative · entry 6

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,503

Underlying: Common Stock · 1,450 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F3 · derivative.exercise_date: A total of 24,108 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-23-016539 · form4-12152023_061201.xml · derivative · entry 5

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,444

Underlying: Common Stock · 653 shares

Expires 2030-09-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

F2 · derivative.exercise_date: A total of 16,097 shares subject to an employee stock option were granted on September 4, 2020, with 10% of this option vested on May 1, 2020, 22.5% vested on May 1 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

SEC source: 0001415889-23-016539 · form4-12152023_061201.xml · nonDerivative · entry 2

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,251

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-23-016539 · form4-12152023_061201.xml · nonDerivative · entry 1

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,354

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-23-016908 · form4-12222023_061202.xml · nonDerivative · entry 1

Gillies Hunter · CIK 0001868997 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,251

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 19, 2023.

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 7

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,346

Underlying: Common Stock · 6,853 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments.

SEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 6

Dake Benjamin T · CIK 0001869248 · SEE REMARKS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,294

Underlying: Common Stock · 1,019 shares

Expires 2031-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.

F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments.